Integrated evidence generation planning is more effective than traditional evidence generation planning. It can help pharmaceutical organizations to improve patient care and outcomes.
With demands for robust and innovative evidence generation from stakeholders continuing to evolve and healthcare systems across the globe under increasing economic pressures, it is vital that pharmaceutical companies adopt a strategic and cross-functional approach to evidence generation.
Oxford PharmaGenesis has extensive experience in supporting clients with the development of integrated evidence generation plans (IEGPs) across a range of therapy areas and for products in different stages of their life cycle.
Download our PDF below to discover:
- how integrated evidence generation planning works
- why pharmaceutical organizations should develop an IEGP now
- how Oxford PharmaGenesis is innovating for the future of IEGPs.
Get in touch with us to learn more about integrated evidence generation planning.